Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases. Its product pipeline include ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for B cell-mediated autoimmune/inflammatory diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the research, development, and commercialization of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Search:
You do not have permission to access this chart.
Please Sign Up or Login
News for Alpine Immune Sciences, Inc. (ALPN)
minutes ago | Banggood.com
58 minutes ago | Aliexpress.com
4 days ago | Zacks Investment Research
4 days ago | Benzinga
4 days ago | Business Wire
a week ago | Business Wire
a week ago | Zacks Investment Research
a month ago | Business Wire
a month ago | Business Wire
2 months ago | Business Wire
2 months ago | Business Wire